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Abstract
The epidemiology and possibly the etiology of bovine spongiform encephalopathy (BSE) have recently been recognized to
be heterogeneous. In particular, three types [classical (C) and two atypical (H, L)] have been identified, largely on the basis of
characteristics of the proteinase K (PK)-resistant core of the misfolded prion protein associated with the disease (PrP
res). The
present study was conducted to characterize the 17 Canadian BSE cases which occurred prior to November 2009 based on
the molecular and biochemical properties of their PrP
res, including immunoreactivity, molecular weight, glycoform profile
and relative PK sensitivity. Two cases exhibited molecular weight and glycoform profiles similar to those of previously
reported atypical cases, one corresponding to H-type BSE (case 6) and the other to L-type BSE (case 11). All other cases were
classified as C-type. PK digestion under mild and stringent conditions revealed a reduced protease resistance in both of
these cases compared to the C-type cases. With Western immunoblotting, N-terminal-specific antibodies bound to PrP
res
from case 6 but not to that from case 11 or C-type cases. C-terminal-specific antibodies revealed a shift in the glycoform
profile and detected a fourth protein fragment in case 6, indicative of two PrP
res subpopulations in H-type BSE. No
mutations suggesting a genetic etiology were found in any of the 17 animals by sequencing the full PrP-coding sequence in
exon 3 of the PRNP gene. Thus, each of the three known BSE types have been confirmed in Canadian cattle and show
molecular characteristics highly similar to those of classical and atypical BSE cases described from Europe, Japan and the
USA. The occurrence of atypical cases of BSE in countries such as Canada with low BSE prevalence and transmission risk
argues for the occurrence of sporadic forms of BSE worldwide.
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Introduction
Prion diseases are invariably fatal neurological diseases that
usually cause severe spongiform change in the brain associated
with an accumulation of a misfolded isoform of the prion protein
(PrP
Sc) [1]. This misfolded isoform is conformationally distinct
from the cellular prion protein (PrP
C) and exhibits a feature
important for diagnostic purposes – the partial resistance to
proteinase K (PK) digestion. The PK-resistant core of PrP
Sc is
denoted as PrP
res [2]. PrP
res is often used for the detection of prion
diseases, and its molecular features are useful to characterize the
type of prion disease in individual cases. PrP
res displays both
variation in molecular size of the residual protein core, based on
variation in the location of PK cleavage sites, and micro
heterogeneity based on differential occupancy of two N-linked
glycosylation sites in PrP. This leads to di-, mono- and
unglycosylated protein subpopulations (glycoforms) that can vary
in relative abundance as assessed by their reactivities on Western
immunoblots. Variation in PK cleavage also results in changes in
immunoreactivity profile of PrP
res, as key epitopes may be present
or absent in the PK-resistant core. Different prion disease types
may also vary in PrP
res conformational stability [3,4].
Until recently, it was widely assumed that bovine spongiform
encephalopathy (BSE) in cattle consisted of only a single,
epidemiologically and biologically homogeneous type. This was
based largely on the fact that experimental transmissions of the
BSE agent to laboratory mice yielded a uniform lesion profile in
the brain with invariable incubation time, irrespective of the
source of BSE inoculum, but also on uniformity of PrP
res
characteristics [5–8]. The lesion profiles and incubation times in
these mice were also undistinguishable from those seen in mice
inoculated with human variant Creutzfeldt-Jakob disease (vCJD).
The PrP
res from these patients and animals also showed similar
molecular weights and glycoform profiles, using Western blot (WB)
analyses [9,10]. These results strongly suggested that BSE was
caused by a single strain of agent, and that exposure to the BSE
agent was the most likely cause of human vCJD [11,12].
However, in 2004, two new ‘‘atypical’’ types of BSE were
identified in Italy and France. The Italian type was named bovine
amyloidotic spongiform encephalopathy (BASE), because of the
unusual and widespread occurrence of PrP
Sc-containing amyloid
plaques in brain tissue [13]. Molecular characterization of the
PrP
res from these cases revealed a more equal ratio of
immunoreactivities for di- and monoglycosylated glycoforms and
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seen in previous BSE cases. Thus indicating a different PK-
cleavage site and supporting the notion of a novel prion disease
type. The lower molecular weight also prompted designation of
such cases as ‘‘L-type’’ BSE, as distinct from classical or ‘‘C-type’’
BSE. The French type had a distinctly higher molecular weight of
PrP
res bands compared to C-type BSE resulting in it being called
high or ‘‘H-type’’ BSE [14]. At least one of these two types of BSE,
together known as atypical BSE, have since been detected in
Germany [3], Japan [15], the Netherlands [2], Poland [16],
Sweden [2], Switzerland [17], the United Kingdom [18] and the
United States [19]; all in cattle 8 years of age and older. Two as-
yet-unclassified cases of atypical BSE have also been reported in
Japan and Belgium [20,21].
Experiments with atypical H- and L-type isolates have
demonstrated their transmissibility to cattle as well as to mice
expressing the bovine prion protein and wild-type mice. These
isolates clearly differ from C-type BSE because they display unique
incubation periods, PrP
res deposition patterns, and patterns of
histological lesions [20,22,23]. While the C-type BSE cases that
occurred as part of the outbreak in the U.K., Europe, Japan and
Canada were believed to be caused by the consumption of
contaminated feedstuffs [24], the origins of H- and L-type BSE are
unknown. It has been speculated that atypical BSE may be
sporadic or genetically caused, and indeed, strong evidence for a
causative role of high-penetrance genetic mutations has been
found in at least one case [25]. Either cause could be linked to the
origin of C-type BSE but the question of origin may never be
definitively answered [23]. The full risks presented to human
health by atypical BSE remain unknown, but data is available
suggesting that L-type BSE may be zoonotic [26,27].
As of November 2009, 17 Canadian cases of BSE have been
confirmed. In order to assess their potential origins and relatedness
to classical and atypical BSE in other countries, an in-depth
analysis of their PrP
res molecular and biochemical features was
performed, including immunoreactivity, glycoform profiles, mo-
lecular size and relative proteinase K sensitivity of their PrP
res
cores [2]. In addition, DNA sequencing was carried out on the full
PrP-coding sequence in exon 3 of the PRNP gene in each of the 17
animals to assess the possibility of causative genetic mutations. The
information obtained provides a better understanding of the
epidemiology of BSE types in Canada and of how similar these
types are to cases identified worldwide.
Materials and Methods
Animals and tissues
Sixteen of the seventeen Canadian BSE cases were detected by
the Canadian BSE surveillance network and were confirmed by
the National BSE Reference Laboratory. All positive cases were
identified by active surveillance using immunohstochemistry (IHC)
or rapid tests approved by the European Food Safety Authority
(EFSA) and the Canadian Food Inspection Agency (CFIA).
Confirmation was based on IHC and immunoblotting of
scrapie-associated fibrils (SAF). Further analyses were done using
a modified Hybrid Western Blot. One Canadian-born case was
detected and confirmed using IHC by the National Veterinary
Services Laboratory in Ames, Iowa, USA. The key details of each
of the 17 Canadian BSE cases are summarized in Table 1.
Tissue preparation and standard Prionics-Check Western
blotting
Brain-stem tissue from each of the 17 cases was sampled at or
close to the level of the obex. This tissue was used to prepare 10%
(w/v) homogenates in 1 x Prionics homogenization buffer
(Prionics-Check Western). Homogenization was performed for
45 s at 23,000 rpm in either a Prypcon container using the
MediFASTH homogenizer (Consul AR) or in a Prioclip container
using the Priogenizer homogenizer (Prionics AG). Initially,
digestion of 100 ml of 10% homogenates was performed by
adding 10 ml of digestion buffer (Prionics-Check Western) and
10 ml of PK (Prionics-Check Western), mixing thoroughly and
incubating for 40 min at 48uC. The reactions were stopped by
successive addition of 10 ml of digestion stop buffer (Prionics-
Check Western), and 100 mlo f2 6sample buffer (Prionics-Check
Western). The samples were mixed well and then heated to 95uC
for 5 min prior to gel electrophoresis and blotting.
Prior to analyses, the PrP
res amounts from each case were equalized
by loading various volumes of the digested samples. Different amounts
of disease-associated protein in each case was due to variables beyond
our control including incubation time and the amount and frequency
of the challenge dose. This step allowed for standardization of each
sample input resulting in a better assessment of antibody immuno-
reactivity and clear protein band profiles for determining molecular
weights and glycoform profiles. The loading amount which produced
the strongest signal with three distinct bands was selected for the
remaining experiments except where otherwise noted.
Each Canadian BSE case was also tested with the Prionics-
Check Western blot using a number of modified protocols, as
described in the following sections. The methods used for
biochemical characterisation are even possible with autolysed
samples which can pose a challenge for histological and
immunohistochemical examination. Field cases are sometimes of
poor tissue quality which can make strain typing based on
morphologic observations very difficult.
Proteinase K sensitivity
To determine the PK sensitivity of PrP
Sc in each of the
Canadian BSE cases, phosphate- and Tris-based buffers (pH 6.5
Table 1. Animal information for the 17 Canadian BSE cases.
Case #
Date
Confirmed
Cattle
Breed
Age
(yrs.)
Initial
Typing
1 05/2003 Angus 5.8 C
2 01/2005 Holstein 8.2 C
3 01/2005 Charolais 6.8 C
4 01/2006 Holstein-Hereford 5.8 C
5 04/2006 Holstein 5.9 C
6 07/2006 Charolais X ,16 H
7 07/2006 Jersey 4.2 C
8 08/2006 Charolais X 8–10 C
9 02/2007 Angus 6.6 C
10 05/2007 Holstein 5.5 C
11 12/2007 Hereford 13.8 L
12 02/2008 Holstein 6.1 C
13 06/2008 Holstein 5 C
14 08/2008 Gelbvieh X 6 C
15 11/2008 Holstein 7.8 C
16 05/2009 Holstein 6.7 C
US 12/2003 Holstein 6.7 C
doi:10.1371/journal.pone.0010638.t001
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pH values were added [2]. After mixing 60 ml of 10% homogenate
with an equal volume of pH-adjustment buffer, the desired pH of
the sample was verified using 20 ml of the sample. Proteinase K
(5 mg/ml) was then added to the pH-adjusted homogenates to
reach a final concentration of 50 mg/ml (Ph 6.5) or 500 mg/ml
(pH 8.0). Digestions were performed for 60 min at 37uC. The
reaction was stopped by the successive addition of 10 mlo f
digestion stop buffer (Prionics-Check Western) and 100 mlo f2 6
sample buffer (Prionics-Check Western). The samples were mixed
well and heated to 95uC for 5 min prior to gel electrophoresis and
blotting.
Deglycosylation with PNGase F
Deglycosylation of PrP
res using peptide N-glycosidase F
(PNGase F; New England Biolabs, USA) was performed following
the manufacturer’s instructions with minor modifications. Briefly,
PrP
res was denatured in a 3% (w/v) sodium dodecyl sulfate (SDS)
solution instead of the denaturing buffer supplied. The treatment
was carried out by incubating PK-digested, denatured PrP
res (5–
10 ml of 10% homogenate) with PNGase F (final concentration
150 U/ml) for 16 hours at 37uC. The samples were mixed well
with an equal volume of 26sample buffer and heated to 95uC for
5 min before proceeding to gel electrophoresis and Western
blotting.
SDS-PAGE, Western blotting
The predetermined amount of each denatured sample (1.25–
10 ml) was loaded on 12- or 17-well pre-cast 1 mm thickness, 12%
Bis-Tris NuPAGE gels (Invitrogen, Canada). Electrophoresis was
performed for 90 min at 100 V in 3-(N-morpholino)propanesul-
fonic acid (MOPS) running buffer (Invitrogen, Canada) with
antioxidant (Invitrogen, Canada) using XCell SureLock Mini-
Cells (Invitrogen, Canada). Magic Mark XP (Invitrogen, Canada)
was used as a reference for molecular mass estimations. Electro-
transfer, antibody binding, and chemiluminescence detection
using CDP-Star and BioMax Light Chemiluminescence film
(Kodak, United Kingdom) were performed following the Prionics-
Check Western kit instructions (Prionics, Switzerland). Film
images were then digitized to quantitate relative glycoform
immunoreactivities using a BioRad ChemiDoc XRS (BioRad,
Canada). The resulting image files were analyzed using the
BioRad Quantity One software version 4.6.3 (BioRad, Canada),
and the integrated optical densities and apparent molecular masses
of the bands were exported for further calculations. Only bands
with molecular masses ranging from 30 to 16 kDa were used to
calculate the glycoform profile, in which the total integrated
optical density of each glycoform band was expressed as a
percentage of the summed integrated optical densities of the three
bands in the triplet.
Antibodies and epitope-specific antibody reactivity
To compare epitope-specific PrP
res antibody reactivities, the
Prionics-Check Western kit specific monoclonal antibody (mAB)
6H4 was replaced in turn by each member of a panel of selected
antibodies. Antibodies 12B2, P4 and SAF32 are PrP N-terminal-
specific antibodies, antibodies 9A2, 6H4 and L42 are PrP core-
specific antibodies and antibodies 94B4 and SAF84 are the PrP C-
terminal-specific antibodies (Table 2).
DNA extraction and sequencing
Genomic DNA was extracted from 0.2–0.4 g unfixed brain tissue
on different days to avoid cross-contamination, using a standard
method (Proteinase K/phenol-chloroform/ethanol precipitation).
PCR primers BTAPRNPDS9:19471U22 and BTAPRNPDS9:
21426L20 were used with published PCR conditions and sequencing
primers [28] to amplify and sequence the entire PrP-coding sequence
located in exon 3 of the bovine PRNP gene from all 17 BSE-
affected cattle, using BigDyeH dideoxy cycle-sequencing chemistry
(Applied Biosystems, USA). Sequence contigs were assembled,
visually inspected and analyzed with LaserGene
TM (DNAStar,
USA) software.
Results
In this study, we analyzed the molecular features of PrP
res using
both a standard and modified Prionics-Check Western Blot
techniques. The characteristics used for typing the Canadian
BSE cases are based on the molecular characterization of natural
BSE case from other countries. Using these characteristics, the
initial confirmatory classifications were supported resulting in 15
C-, 1 H- and 1 L-type Canadian BSE cases.
Molecular weights and glycoform profiles of PrP
res
As part of the initial confirmation, all Canadian BSE cases were
classified as C-, H-, or L-type on the basis of PrP
res molecular
weights and relative antibody immunoreactivities. In the 15
Canadian C-type BSE cases, the mean (6 SD) relative
immunoreactivities of di-, mono-, and unglycosylated moieties
were 62.565.8, 25.662.5 and 12.064.5%, respectively. The
Table 2. Antibodies used to determine differential immunoreactivity.
Antibody Eliciting Peptide Target Epitope Epitope reference Source/Working Conc.
12B2 bovine PrP 97-115 101WGQGG105 [33] J. Langeveld, CVI/0.5 mg/ml
P4 ovine PrP 89-104 85WGQGGSH93 [34] Rida/Germany/0.2 mg/ml
SAF 32 ovine PrP59-89 62/70/78/86QPHGGGW68/76/84/92 [35] SPI-BIO, France/0.1 mg/ml
9A2 bovine PrP 97-115 110WNK112 [33] J. Langeveld, CVI/0.5 mg/ml
6H4 ovine PrP148-157 156DYEDRYYREN164 [36] Prionics AG/Kit dilution
L42 ovinePrP145-163 156YEDRYY161 [37] Rida, Germany/0.02 mg/ml
94B4 ovine PrP190-197 198HTVTTTTK205 [2] J. Langeveld, CVI/0.2 mg/ml
SAF84 bovine PrP145-169 175RPVDQY180 [35] J. Grassi, CEA/1.0 mg/ml
The antibodies used can be organized into three groups based on their target epitope. The N-terminal-specific antibodies include 12B2, P4, and SAF32, core-specific
antibodies are 9A2, 6H4, and L42, and the C-terminal-specific antibodies are 94B4 and SAF84.
doi:10.1371/journal.pone.0010638.t002
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17.660.6 kDa for the di-, mono- and unglycosylated bands,
respectively. In the L-type case, the relative immunoreactivities
were 39.360.6, 35.061.0 and 26.361.2%, and estimated
molecular masses of the di-, mono- and unglycosylated moieties
were all slightly lower (by ,1 kDa) than those of the C-type, at
26.360.6, 20.760.6 and 17.360.6 kDa, respectively. The single
H-type case had higher molecular masses (by ,1.5 kDa) for all
three bands, with di-, mono- and unglycosylated forms at
28.761.5, 23.361.2 and 19.361.2 kDa, respectively. When using
core-specific or N-terminal-specific antibodies, the glycoform
profile of the Canadian H-type case resembled the C-type cases
with 58.362.5% digycosylated, 29.360.6% monoglycosylated,
and 12.763.5% unglycosylated PrP
res. When using a C-terminal
antibody, however, the molecular weight (27.760.6, 22.760.6
and 17.760.6 kDa) was more similar to that of the C-type, and the
glycoprofile (38.360.6, 36.760.6 and 25.061.0%) was more
similar to the L-type BSE cases.
To directly compare the PrP
res glycoform ratios from each case,
the mean proportion of diglycosylated glycoform immunoreactiv-
ity was divided by the mean proportion of monoglycosylated
glycoform immunoreactivity [16,29]. In the Canadian L-type case,
this ratio was 1.1. When this ratio was determined for the C- type
cases, the values ranged from 2.1 to 3.7. The H-type ratio was
similar to that of the C-types when using a core-specific antibody
with a value of 2.0, however when using a C-terminal antibody
this ratio shifted down to a value of 1.2 (Table 3).
Deglycosylation
Variations in the molecular weights of the PrP
res core associated
with atypical BSE cases are often difficult to determine when all
glycoforms are present, especially in L-type BSE which often
displays a subtle band shift. Removal of the carbohydrate moieties
from PrP
res offers a way to enhance the estimates of the molecular-
weight shifts in the L- and H-type PrP
res cores.
For each of the BSE types, PNGase F treatment resulted in a
subtle change in electrophoretic migration of the deglycosylated
band when compared to the naturally occurring unglycosylated
isoform (Fig. 1). None of the PNGase-treated samples showed
complete removal of all carbohydrates, and the susceptibility to this
treatment appeared type-dependent with the L-type Canadian BSE
beingthemost completelydeglycosylated.Deglycosylationofthe H-
type PrP
res also resulted in the presence of two unglycosylated
protein isoforms when using C-terminal antibodies for detection,
one at 19 kDa and the other at 10 kDa (data not shown).
Resistance to PK digestion
Proteinase K (PK) digestion under mild and stringent conditions
revealed that the misfolded prion protein from C-type BSE is more
PK-resistant than that from H- or L-type atypical BSE. Under
mild conditions, the full-length PrP
C was completely degraded,
while PrP
Sc was converted to readily visualized amounts of PrP
res
for all of the BSE cases. Under stringent conditions in contrast, the
remaining film signals of L- and H-type PrP
res decreased
significantly, while that of the C-type PrP
res remained nearly at
the same level. Densitometric quantification revealed that the C-
type BSE PrP
res only decreased by approximately 10% under the
stringent conditions while the decrease in surviving PrP
res was
greater than 50% for both L- and H-type cases (Fig. 2).
Investigation of PrP
res immunoreactivities using different
antibodies
When N-terminal-specific, C-terminal-specific and core-specific
antibodies were compared for their relative abilities to detect
PrP
res in the different types of BSE, further evidence supporting
the initial classification of the different BSE types was established.
The N-terminal-specific antibodies 12B2, P4 and SAF32 bound to
all three bands of PrP
res in H-type BSE, but very weakly or not at
all to the PrP
res bands of the C- or L-type BSE. The core-specific
and C-terminal-specific antibodies 9A2, L42, 6H4, 94B4 and
SAF84 bound to all three bands of the PrP
res of the H-, L-, and C-
type BSE (Table 4). Both C-terminal-specific antibodies also
bound to a fourth band at around 10 kDa in the H-type BSE case.
Table 3. Glycoform quantification of PrP
res from the
Canadian BSE cases using core antibody 6H4.
CASE/
Type D M Un D/M
CASE/
Type D M Un D/M
1(C) 60.9 27.1 12.0 2.2 9(C) 75.6 20.4 4.2 3.7
2(C) 61.0 26.7 12.2 2.3 10(C) 61.1 24.8 14.1 2.5
3(C) 56.2 27.0 16.9 2.1 11(L) 39.3 35.0 26.3 1.1
4(C) 58.3 26.7 15.0 2.2 12(C) 60.7 27.4 11.9 2.2
5(C) 58.1 24.7 17.2 2.4 13(C) 58.4 25.8 15.8 2.3
6(H) 58.3 29.0 12.7 2.0 14(C) 61.7 23.3 15.1 2.6
7(C) 75.2 20.3 4.5 3.7 15(C) 63.9 28.8 7.1 2.2
8(C) 58.6 25.6 15.8 2.3 16 (C) 61.0 26.8 12.2 2.3
US
case (C)
66.5 28.2 5.3 2.4
The proportion of PrP
res detected as diglycosylated is approximately 60% for
the C- and H-type. In comparison, the L-type had a much lower proportion of
the diglycosylated PrP
res at approximately 40%. The L-type case also had a ratio
of di- to monoglycosylated (D/M) PrP
res well below 2 (1.1), whereas the ratios of
intensity of D/M from all other cases were above or equal to 2 when using core
specific antibodies for detection. Profiles were determined by analyzing
western blot reactivity using the BioRad Quantity One software (BioRad,
Canada).
D = Diglycosylated PrP
res; M = Monoglycosylated PrP
res; Un = Unglycosylated
PrP
res; D/M = Diglycosylated PrP
res/Monoglycosylated PrP
res.
doi:10.1371/journal.pone.0010638.t003
Figure 1. Western blot analysis of Canadian BSE after PK
digestion and PNGase F treatment. L- (case 11, lanes 1 and 2), C-
(case 12, lanes 3 and 4) and H- (case 6, lanes 5 and 6) type BSE after PK
digestions with (+) and without (2) PNGase F deglycosylation. Core
antibody 6H4 detection demonstrates the size differences between
classical and atypical BSE and also a slight size shift between the
unglycosylated and deglycosylated bands within each individual type
of BSE. The lane labelled as M contains the molecular weight marker
and weights are in kilodaltons.
doi:10.1371/journal.pone.0010638.g001
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A summary of diploid genotypes of the PrP-coding regions in
PRNP exon 3 is provided in Table 5 for each of the 17 BSE cases
in relation to a reference sequence (GenBank accession AJ298878).
Although 4 previously known polymorphisms were observed, all of
these were either translationally silent (CAG«CAA in codon 78,
CCC«CCT in codon 113 and AAC«AAT in codon 192) or
have been shown previously to have no phenotypic association
with BSE (OPR region carrying either 5 or 6 tandem repeat units).
Discussion
The classification of BSE types based on molecular and
biochemical properties involves molecular weight determination
of PrP
res. Atypical BSEs have a higher or lower apparent
molecular mass of PrP
res when compared to C-type BSE using
WB analysis with core-specific antibodies. Such differences are in
the range of 0.9 to 1.3 kDa for the H-type, but rather subtle for
L-type (,0.3 kDa) [2,3,7,10]. The Canadian H-type BSE case,
detected in 2006, displays an obvious molecular weight shift of
around 1.3 kDa, similar to that observed in some cases in other
countries [2,3]. A lower molecular mass of PrP
res for L-type BSE
compared with C-type BSE has been recorded in cases from
Italy, France, Japan, German, Poland and the Netherlands
[2,3,13,15,16,20,29]. The Canadian L-type BSE case has a subtle
molecular weight shift downward compared to Canadian C-type
cases, which made it initially challenging to confirm and additional
supporting evidence was necessary.
PNGase F treatment to remove associated carbohydrates from
glycosylated PrP
res, which is intended to generate a single
unglycosylated protein species for more precise molecular-weight
estimation, provided further support for the size shifts in Canadian
H- and L-type BSE cases detected in the initial analyses. Removal
of carbohydrates also confirmed the presence of two sizes of
unglycosylated PK-resistant fragments, at approximately 19 and
10 kDa, in the H-type case. Similar behaviour has been previously
observed and was explained by the possibility of two subpopula-
tions of PrP
Sc carrying two available PK-cleavage sites with
different susceptibilities to digestion in H-type cases [2]. PNGase F
treatment results in some residual glycosylated PrP
res, even under
the most highly denaturing conditions. Susceptibility to deglyco-
sylation was noted to be associated with BSE type, with PNGase F
treatment being most effective on the L-type case and less effective
on the H- and C-type Canadian cases. Presuming that
glycosylation occurs on the same amino acid residues in all cases,
this may be related to differences in the conformation and/or
conformational stability of the different BSE types.
Another interesting observation in the deglycosylation experi-
ments was the slightly lower migration rate of the deglycosylated
band of each BSE type after treatment with PNGase F compared
to the rate for the unglycosylated band in untreated samples
(Fig. 1). This is believed to result from the N-linked carbohydrate
removal process, which alters asparagine to aspartic acid and thus
reduces electrophoretic mobility of protein-detergent complexes
due to a decrease in the SDS:PrP
res molar ratio [2].
While removing carbohydrate groups is useful for molecular
weight analysis, retaining these post-translational modifications is
also valuable for BSE strain typing. In general, L-type BSE cases
Figure 2. Western blot analysis of Canadian BSE after mild and
stringent PK digestion. L- (case 11, lanes 1 and 2), C- (case 12, lanes 3
and 4) and H- (case 6, lanes 5 and 6) type BSE after PK digestions at 37uC
for one hour under mild (Mild: pH 6.5, PK 50 mg/ml) and stringent (Str.:
pH 8.0, PK 500 mg/ml) conditions. Core antibody 6H4 detection
demonstrates little change in the amount of PrP
res surviving the
stringent digestion in C-type BSE and a significant degradation of L-
type PrP
res and almost complete degradation of H-type PrP
res under the
stringent conditions. The lane labelled as M contains the molecular
weight marker and weights are in kilodaltons.
doi:10.1371/journal.pone.0010638.g002
Table 4. Western blot PrP
res immunoreactivity profiles for the Canadian BSE cases.
Ab 1C 2C 3C 4C 5C 6H 7C 8C 9C 10C 11L 12C 13C 14C 15C 16C US C
12B2 * * * * * *** — * — * * * * * — — —
P 4 — — —— —* * —— — — — ——— — ——
S A F 3 2 ——— —— * *— ——— —— — ——— —
9A2 *** *** *** *** *** *** ** *** ** *** *** *** *** *** *** *** ***
6H4 **** **** **** **** **** **** *** **** ** **** **** **** **** **** **** **** ****
L42 *** *** *** *** *** *** ** *** * *** *** *** *** *** *** *** ***
94B4 *** *** *** *** *** *** ** *** * *** *** *** *** *** *** *** ***
SAF84 *** *** *** *** *** *** ** *** * *** *** *** *** *** *** *** ***
When using N-terminal-specific, C-terminal-specific and core-specific antibodies to compare their affinity to the different types of BSE, N-terminal-specific antibodies P4,
12B2 and SAF32 bound to all three bands of PrP
res in H-type, but not to the PrP
res bands of the C- or L-type cases. The core- and C-terminal-specific antibodies 9A2, L42,
6H4, 94B4, SAF84 bound to all three bands of the PrP
res of the H-, L-, and C-types.
****All three bands of PrP
res were visible and strongly reactive;
***All three bands of PrP
res were visible;
**Two of the three bands of PrP
res were visible;
*One of the three bands of PrP
res was visible; - None of the PrP
res bands were visible; Ab = Primary antibody.
doi:10.1371/journal.pone.0010638.t004
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proportion of diglycosylated PrP
res and a larger proportion of
mono- and unglycosylated PrP
res when compared to C- and H-
type [2,3,13,16,20,29]. This more balanced di- to monoglycosy-
lated ratio is also seen in the Canadian L-type BSE case. In
Canadian C-type and H-type cases, the average ratio of di- to
monoglycosylated PrP
res is consistently $2, while in the L-type
case it is ,1.5. When using C-terminal antibodies however, the
Canadian H-type BSE di- to monoglycosylated ratio shifted closer
to the L-type ratio. It was recently suggested that this may reflect
the presence of a second population of PrP
res in H-type BSE with a
slightly lower molecular weight [30]. This would result in the
second population’s diglycosylated band merging with the
monoglycosylated band of the first population increasing its
apparent abundance. Based on the fact that the altered
glycoprofile and fourth band are only seen with C-terminal
antibodies [30], it seems that this second PrP
res population is
cleaved between the epitopes detected by the core-specific and C-
terminal-specific antibodies which could result in the observed
,10 kDa size shift.
Conformational stability can also vary in different prion disease
strains. This can be analyzed in different ways, but one of the
simplest is to determine the proteinase K sensitivity of the
misfolded protein using mild and stringent conditions [2]. The H-
and L-type BSE isolates displayed higher susceptibilities to PK
digestion than the C-type isolates, suggesting that the conforma-
tion of the Canadian C-type BSE is more stable than the two
atypical forms. This is similar to results from comparable analyses
on C-type and atypical BSE done elsewhere [2,21].
Proteinase K digestion under mild conditions induces N-
terminal cleavage of PrP
Sc in all three BSE types to varying
degrees. Selecting antibodies with epitopes localized on either side
of the cleavage sites allows for another mechanism of BSE type
differentiation. It has been demonstrated that C- and L-type BSE
react only weakly with antibodies directed towards the N-terminal
portion of PrP
res (e.g., 12B2 antibody [2,16]). This was also shown
for Canadian cases. When testing Canadian H-type BSE, as is the
case with other H-type BSE cases, there is strong binding with the
N-terminal antibodies including 12B2, P4 and SAF32. Another
similarity between Canadian H-type BSE and those found in other
countries is the detection of a fourth band at approximately
10 kDa when using C-terminal-specific antibodies. This unique
behaviour of H-type BSE needs further investigation to determine
its source and what implications this may have on other H-type
characteristics such as pathogenetic traits.
In May 2003, after the detection of the first indigenous case of
BSE, Canadian surveillance was modified to increase test numbers
to demonstrate the extremely low level of BSE in the country. This
additional effort primarily targets ‘‘4D’’ cattle over 30 months of
age. This includes animals that are dead, non-ambulatory (down),
sick at ante mortem inspection (diseased), or presented for emergency
slaughter (distressed). The program also includes animals of any
age presenting clinical signs consistent with BSE. As of November
2009, this program had tested over 275,000 cattle as negative and
16 cattle as positive for BSE. An additional case was detected in
the United States and traced back to Canada, for a total of 17
Canadian-born cases. The aim of our study was to provide an in-
depth analysis of the molecular and biochemical properties of the
PrP
res associated with each of these cases and thus insight into the
epidemiology of BSE in Canada. We confirmed the diagnoses of
15 C-, 1 L- and 1 H-type BSE cases by determining molecular
mass, immunoreactivity, proteolytic sensitivity (stability) and
glycoform profile.
In addition to shared molecular characteristics, a common
feature of the majority of atypical BSE cases worldwide is their
occurrence in older animals as compared to C-type BSE which is
found in various age groups [16]. Most atypical BSE cases have
occurred in animals over 8 years old with an average age of 12
years [2,3,10,13,15,16,29]. The Canadian atypical BSE cases
occurred in a 16-year-old Charolais (H-type) and a 13.8-year-old
Polled Hereford (L-type), both with clinical disease at the time of
sampling. French, Italian, Dutch, Polish, and German atypical
BSE cases have occurred in healthy slaughter animals but have
also been reported among fallen stock, and these might have
displayed unreported clinical abnormalities [2]. This variation in
clinical presentation adds to the list of questions that remain
unanswered for these types of BSE.
The origin of atypical BSE is unknown, but sporadic, infectious
and genetic mechanisms have all been suggested. Several groups
have argued that these cases may represent the existence of a
sporadic prion disease in bovines, perhaps similar in etiology to
sporadic Creutzfeldt-Jakob disease in humans [2,6,12,19]. Exper-
imental infection of cattle with an isolate of naturally occurring
British sheep scrapie resulted in differences in the PrP
res
electrophoretic profiles compared to classical C-type BSE which
led to the suggestion that atypical BSE may be a result of
transmission of a prion disease from a different natural host into
cattle [14]. In addition, an American H-type BSE case with a
mutation (E211K) in the PRNP gene has been reported [19]. This
represents the first case of BSE with a potentially pathogenic
mutation within the bovine PRNP gene, and experiments are
underway to determine the potential importance of this mutation
in the development of prion disease in cattle [19]. We did not
observe such mutations in the Canadian BSE cases analyzed as of
November 2009, and negative results of a large population survey
Table 5. Genotypes of Canadian BSE-affected cattle at
polymorphic positions in the protein-coding sequence of
PRNP.
PrP Codon(s)
Sequence OPR (54–103) 78 (Gln) 113 (Pro) 192 (Asn)
AJ298878 6 CAG CCC AAC
Case 1 .. .. CCY ..
Case 2 .. CAA .. ..
Case 3 .. .. .. ..
Case 4 .. CAR .. ..
Case 5 .. CAA .. ..
Case 6 .. .. .. ..
Case 7 .. .. .. ..
Case 8 .. .. .. AAY
Case 9 .. CAR .. ..
Case 10 .. .. .. ..
Case 11 .. CAR .. AAY
Case 12 .. .. .. ..
Case 13 .. CAR .. ..
Case 14 .. CAR .. ..
Case 15 .. .. .. ..
Case 16 6/5 CAG/– .. ..
US Case .. .. .. AAY
AJ298878 = GenBank reference sequence; OPR = octapeptide repeat; .. =
homozygous for AJ298878 sequence; – = codon 78 missing on 5-OPR allele.
doi:10.1371/journal.pone.0010638.t005
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in North American cattle [31]. However, the intrinsically
recurrent nature of genetic mutation, as shown particularly for
the homologous E200K mutation known to cause genetic
Creutzfeldt-Jakob disease in humans [32], means that the
possibility that a small subpopulation of cattle that carry such
mutations exist cannot be eliminated.
Our results indicate that the range of molecular characteristics
of misfolded PrP in Canadian BSE cases is very similar to that
observed in other countries and suggests a number of criteria to
use when typing BSE cases (Table 6). It is also interesting that the
Canadian atypical BSE cases match so well with cases from other
countries in terms of their epidemiological profiles, including
detection in older animals and no definitive cause of disease.
Ongoing inoculation studies with Canadian BSE types in cattle
and transgenic mice will provide clarification on how similar these
isolates are after transmission using defined and controlled
experimental inoculations. These studies should help to answer
some of the many outstanding questions about atypical BSE and
aid in policy development to reduce the risk of atypical BSE
transmission to animals and humans.
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